POST Online Media Lite Edition



 

Australia: Ezy Company fined for alleged unlawful importat of COVID rapid antigen tests, nicotine vaping products

Christian Fernsby |
The Therapeutic Goods Administration (TGA) has issued two infringement notices, totalling $26,640, to Melbourne-based company Ezy Company Pty Ltd (trading as Ezy Vapes) for alleged importation breaches relating to COVID-19 rapid antigen tests and nicotine vaping products.

Article continues below



Topics: AUSTRALIA   

It is alleged that Ezy Company Pty Ltd imported COVID-19 rapid antigen tests and nicotine vaping products that were not included in the Australian Register of Therapeutic Goods (ARTG) at the time of importation.

Under the Therapeutic Goods Act 1989 (the Act), therapeutic goods such as nicotine vaping products and COVID-19 rapid antigen tests must be included in the ARTG before they can be lawfully imported into Australia, unless a specific exemption or approval applies.

COVID-19 rapid antigen tests and nicotine vaping products also have additional requirements to be appropriately and lawfully accessed.

In addition to being included in the ARTG (unless an exemption, approval or authority applies), all importers of COVID-19 test kits must apply for, and be granted, a biosecurity import permit unless they can demonstrate that the goods are for personal use only or, for lateral flow test kits, meet the import conditions published on the Australian Biosecurity Import Conditions (BICON)

Since 1 October 2021, consumers require a valid prescription from a doctor in Australia to legally import nicotine vaping products. A valid prescription continues to be required to purchase nicotine vaping products from Australian pharmacies.

It remains illegal for other Australian retailers to sell nicotine vaping products to consumers.


What to read next

AG Brnovich obtains $22.5 million judgment and injunction against Eonsmoke
University of Miami to pay $22m to settle medically unnecessary laboratory tests, fraudulent billing practices
Three pharmaceutical companies to pay over $122m to resolve allegations that they paid kickbacks